Humalog® Mix50/50(tm) as a Treatment for Gestational Diabetes
Primary Purpose
Gestational Diabetes Mellitus
Status
Completed
Phase
Phase 4
Locations
Study Type
Interventional
Intervention
Insulin LISPRO
Insulin, Long-Acting and Insulin
Sponsored by
About this trial
This is an interventional treatment trial for Gestational Diabetes Mellitus focused on measuring gestational diabetes mellitus, insulin analogues in pregnancy
Eligibility Criteria
Inclusion Criteria:
- Pregnant and at least 13 weeks gestation
- Diagnosed with gestational diabetes mellitus
- Failed diet therapy
Exclusion Criteria:
- <18 years old or over 45 years old
- urine dipstick >2+ protein
- blood pressure >140/80 mmHg
- hematocrit <30%
- refusal to take insulin
- inability to understand instructions or to consent to participate.
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
Mix 50/50
Usual insulin regimen
Arm Description
Insulin LISPRO: 3 doses of Humalog® Mix50/50™ at mealtime.
Usual insulin regimen of insulin, Long-Acting and Insulin: 3 injections of Humalog(r) daily with meals; 3 injections of Humulin N (r) daily on rising, mid-afternoon, and at bedtime
Outcomes
Primary Outcome Measures
Hemoglobin A1C
Compare the efficacy and safety of three daily injections of Humalog® Mix50/50TM to six daily injections of Humalog® and Humulin N® insulin, by hemoglobin A1C.
Secondary Outcome Measures
Birthweight of Infant
Birthweight of infant born to mother with gestational diabetes using insulin
Full Information
NCT ID
NCT01613807
First Posted
June 5, 2012
Last Updated
June 7, 2022
Sponsor
Sansum Diabetes Research Institute
Collaborators
Eli Lilly and Company
1. Study Identification
Unique Protocol Identification Number
NCT01613807
Brief Title
Humalog® Mix50/50(tm) as a Treatment for Gestational Diabetes
Official Title
Phase 4 Humalog® Mix50/50(tm) for the Treatment of Insulin Requiring Gestational Diabetes
Study Type
Interventional
2. Study Status
Record Verification Date
June 2022
Overall Recruitment Status
Completed
Study Start Date
October 2008 (undefined)
Primary Completion Date
June 2010 (Actual)
Study Completion Date
October 2010 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Sansum Diabetes Research Institute
Collaborators
Eli Lilly and Company
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
Evaluation of the Safety and Efficacy of Humalog® Mix50/50TM administered as 3 injections daily to Humalog® plus Humulin N® insulin administered as 6 separate injections daily in terms of glucose control for women with Gestational Diabetes.
Detailed Description
Controlling hyperglycemia during pregnancy decreases the risk of adverse neonatal and maternal outcomes. Not only must fasting glucose be normalized, but clinical evidence also indicates that controlling postprandial hyperglycemia will significantly reduce the risk of adverse neonatal and maternal outcomes.
Standard therapy to achieve near-normal glycemia in gestational diabetes involves combining intermediate-acting basal (NPH) insulin with rapid-acting insulin (insulin lispro), thereby requiring 6 daily injections. Premixed Humalog® Mix50/50TM has the potential advantage over combination rapid-acting plus NPH insulin because it involves fewer injections, and those injections are associated with mealtime. The potential downside to the premixed formulation is nocturnal hypoglycemia associated with the time lag between the dinner and breakfast dose. This study will evaluate the efficacy and safety of Humalog® Mix50/50TM compared to that of Humalog® plus Humulin N® insulin for the treatment of insulin-requiring patients with gestational diabetes mellitus, while monitoring glucose control, intrauterine growth and assessing pregnancy outcomes.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Gestational Diabetes Mellitus
Keywords
gestational diabetes mellitus, insulin analogues in pregnancy
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
40 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Mix 50/50
Arm Type
Experimental
Arm Description
Insulin LISPRO: 3 doses of Humalog® Mix50/50™ at mealtime.
Arm Title
Usual insulin regimen
Arm Type
Active Comparator
Arm Description
Usual insulin regimen of insulin, Long-Acting and Insulin: 3 injections of Humalog(r) daily with meals; 3 injections of Humulin N (r) daily on rising, mid-afternoon, and at bedtime
Intervention Type
Drug
Intervention Name(s)
Insulin LISPRO
Other Intervention Name(s)
Humalog® Mix50/50™
Intervention Description
Humalog® Mix50/50™ [50% insulin lispro protamine suspension and 50% insulin lispro injection, (rDNA origin)], three times daily at mealtime. Dose determined by blood glucose history.
Intervention Type
Drug
Intervention Name(s)
Insulin, Long-Acting and Insulin
Other Intervention Name(s)
Humalin N(r), Humalog (r)
Intervention Description
Usual insulin regimen: Long-acting insulin three times daily on rising, mid-afternoon, and before bed, and insulin lispro three times daily at mealtime. Doses determined by blood glucose history and carbohydrate content of the meal.
Primary Outcome Measure Information:
Title
Hemoglobin A1C
Description
Compare the efficacy and safety of three daily injections of Humalog® Mix50/50TM to six daily injections of Humalog® and Humulin N® insulin, by hemoglobin A1C.
Time Frame
During Pregnancy (at approximately 28 weeks gestation)
Secondary Outcome Measure Information:
Title
Birthweight of Infant
Description
Birthweight of infant born to mother with gestational diabetes using insulin
Time Frame
End of pregnancy
10. Eligibility
Sex
Female
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
44 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Pregnant and at least 13 weeks gestation
Diagnosed with gestational diabetes mellitus
Failed diet therapy
Exclusion Criteria:
<18 years old or over 45 years old
urine dipstick >2+ protein
blood pressure >140/80 mmHg
hematocrit <30%
refusal to take insulin
inability to understand instructions or to consent to participate.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Kristin Castorino, DO
Organizational Affiliation
Sansum Diabetes Research Institute
Official's Role
Principal Investigator
12. IPD Sharing Statement
Learn more about this trial
Humalog® Mix50/50(tm) as a Treatment for Gestational Diabetes
We'll reach out to this number within 24 hrs